Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
Based on its current expectations, the Company believes its capital resources as of September 30, 2013 will be sufficient to fund its currently planned operations into 2015 and through the expected release of final survival results from both the Synergy and Borealis-1 trials. The cash burn is expected to be reduced in 2014 compared with 2013 because the company-sponsored Borealis-1 trial is expected to incur the majority of its costs in 2013. Further, the investigator-sponsored OGX-427 Phase 2 trials are substantially less capital-intensive than company-sponsored trials.
At November 7, 2013, The Company had 14,707,636 shares outstanding.
Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012Collaboration revenue$
,315Operating expenses: Research and development18,00412,89542,12224,303 General and administrative2,4731,9657,4465,749Total operating expenses20,47714,86049,56830,052Loss from operations(10,615)(8,290)(28,290)(19,737) Other income5612,3703,1192,742Net loss$
(16,995)Basic and diluted net loss per share$
(1.29)Weighted average number of basic and diluted common shares14,690,98414,619,84214,675,24413,141,940Consolidated Balance Sheets(In thousands) September 30, December 31, 20132012 (unaudited) Assets: Cash, cash equivalents, short term investments and restricted cash$
75,697 Interest receivable295327 Amounts receivable9,922714 Prepaid expenses and other current assets2,7133,755 Property, equipment and other assets1,6181,523Total assets$
82,016Liabilities and stockholder
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study2
. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 20123
. OncoGenex to Present at Credit Suisse Healthcare Investor Conference4
. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting5
. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie6
. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication7
. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference8
. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference9
. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock10
. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference11
. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner